Pregabalin Capsule
Product Images NDC 71335-1792

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1792). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351792)

Pregabalin Capsules, USP 150 mg oral capsules label by Bryant Ranch Prepack. The label shows the NDC 71335-1792-01, a 30-capsule count, and indicates it is Rx only. The manufacturer logo for BRP Pharmaceuticals is also visible, along with storage instructions and a barcode.*

FDA Label Image

Label (Lbl7133517922)

Pregabalin 150 mg capsule label for human prescription drug packaged by Bryant Ranch Prepack in Burbank, CA. The label indicates the capsule is white, compares to Lyrica 150 mg by Hetero Labs Limited, and contains 30 capsules. Storage instructions recommend room temperature 20°-25°C (68°-77°F). The product NDC is 71335-1792-1.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line chart depicting the percent of patients improved on the vertical axis plotted against percent improvement in pain from baseline on the horizontal axis. The chart compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and a placebo group, showing varying levels of patient improvement over the percent pain improvement range.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR versus days for Pregabalin and Placebo groups over a period of 180 days. The y-axis represents the estimated percentage of subjects without LTR, decreasing over time, and the x-axis shows the number of days from 0 to 180.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line chart comparing the percent of subjects improved from baseline to week 12 using the Brief Overall Change in Functioning (BOCF) method for Pregabalin and Placebo groups. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved. Two lines depict the results: a solid line for Pregabalin and a dashed line for Placebo, illustrating greater improvement with Pregabalin over placebo.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A comparative line graph showing the percent of subjects improved over time from baseline to week 16. The x-axis represents the percent improved, and the y-axis shows the percent of subjects improved, with two lines comparing Pregabalin and Placebo. The solid line indicates Pregabalin, and the dashed line represents Placebo.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph depicting the percent improvement in pain from baseline against the percent of patients improved. It compares two groups: patients taking Pregabalin 150 mg three times a day and a placebo group. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The graph illustrates trends of pain improvement across these groups, with lines labeled accordingly.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo. The graph shows trends in patient improvement percentages over different levels of pain improvement.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing the percent of patients improved versus the percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating differences in pain improvement over varying percent thresholds.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) across different doses of pregabalin and placebo in two studies labeled Study E1 and Study E3. The x-axis shows groups including placebo and various pregabalin dosages, while the y-axis represents responder rates percentage. Statistical significance is noted with asterisk marks indicating comparisons to placebo.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A dose-response line graph showing seizure reduction (median % change from baseline) on the vertical axis versus daily dose (mg/day) on the horizontal axis for Pregabalin. The graph compares seizure reduction across four different study groups labeled Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, with markers and p-values indicating statistical significance at multiple dose levels up to 600 mg/day.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares placebo and three Pregabalin daily doses (300 mg, 450 mg, and 600 mg). The vertical axis shows the percent of patients improved, and the horizontal axis shows percent pain improvement from baseline, with markers at intervals from 0 to 100% improvement.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of the active ingredient Pregabalin, showing its molecular form with amino, carboxyl, and hydrocarbon groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.